(CYTR-DD) Mkt-Cap $9.8 M--Cash $18.5 M or untill 2023+ --HUGE Pipeline with multiple Phase 3 & Phase 2 programs targeting Rare Disease and Cancer(links to pipeline charts below) . First NDA & MAA submission expected in Q2 for a Rare Disease (Niemann-Pick Disease) with potential approval in Q4 in USA and Europe which will trigger $10 million milestone payment + royalties to CYTR .Multiple clinical trial readouts expected during first half of this year (more infos below).
This MASSIVE underpriced low float stock could easily rise more than tenfold in the coming months on positive clinical results and approvals . Again Market cap is less than $10 million trading 80% below Cash balance which makes this stock more than a PURE GIFT .STRONG BUY SUPER AGGRESSIVE ,, from current sp its almost a slam dunk .GL
CytRx (CYTR)
Market-Cap: $9,8 M
Cash: $18,5 M ( Cash untill 2023+)
Price: $0,29
Shares Out: 33,6 M
Burn-rate: only $1.2 M per Quarter
NO DEBT
Presentation December 2019
cytrx.com
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin ....December 19, 2019
cytrx.com
CytRx Corporation - Biopharmaceutical Company Discusses Near Term Value from Out-License Deals and Growth Drivers
stocknewsnow.com
Orphazyme’s arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
finance.yahoo.com
Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
finance.yahoo.com
CYTR-- Arimoclomol Pipeline (partnered with Orphazyme for $120 Million in potential Milestones + Royalties)
CYTR-- Aldoxorubicin Pipeline (partnered with ImmunityBio for $340 Millon in potential Milestones + Royalties)
 |
